Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure drug vericiguat put to the test in everyday care

NCT ID NCT06486844

Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 01, 2026 · Updated 3 times

Summary

This study looked at data from 500 people in Germany who started taking vericiguat for chronic heart failure with reduced ejection fraction. Researchers wanted to see how well the drug works outside of clinical trials, in routine medical care. They tracked deaths and hospitalizations to measure real-world effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
vericiguat (Verquvo)
What this could lead to
If successful, this study could confirm that vericiguat works as well in everyday practice as it did in clinical trials, helping doctors better manage heart failure.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It also only looks at existing data, so it cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

500 people

The number who actually took part.

Started

Jul 2024

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients with their first vericiguat prescription since market authorization in September 2021 who are aged 18 years or older will be included in the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with an initial prescription of Vericiguat (index date) according to ATC Code C01DX22. * At least 18 years or older on the initial prescription of Vericiguat. Exclusion Criteria: * No exclusion criteria for any population will be applied.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic heart failure with reduced ejection fraction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic heart failure with reduced ejection fraction

Contacts and locations

Locations

  • Bayer

    Wuppertal, 42096, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.